Who are risedronate combine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ibandronate IV, Ibandronate (Bondronat), Risedronate Sodium (Actonel), elmex gel, elmex® gelée, Marketed Cavity Protection Toothpaste.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/risedronate-combine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

risedronate combine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

risedronate combine (risedronate combine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bisphosphonate. Area: Osteoporosis.

phase 3 Bisphosphonate Hydroxyapatite Osteoporosis Small molecule Live · refreshed every 30 min

Target snapshot

risedronate combine (risedronate combine) — Hanlim Pharm. Co., Ltd.. Risedronate combines with other medications to inhibit bone resorption by acting on osteoclasts.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
risedronate combine TARGET	risedronate combine	Hanlim Pharm. Co., Ltd.	phase 3	Bisphosphonate	Hydroxyapatite
Ibandronate IV	Ibandronate IV	National Taiwan University Hospital	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase; hydroxyapatite in bone
Ibandronate (Bondronat)	Ibandronate (Bondronat)	Chinese Society of Lung Cancer	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase; hydroxyapatite in bone
Risedronate Sodium (Actonel)	Risedronate Sodium (Actonel)	Sanofi	marketed	Bisphosphonate	Farnesyl pyrophosphate synthase (indirect); hydroxyapatite binding
elmex gel	elmex gel	Hadassah Medical Organization	marketed	Topical fluoride agent	Tooth enamel (hydroxyapatite)
elmex® gelée	elmex® gelée	Gaba International AG	marketed	Topical fluoride agent	Tooth enamel hydroxyapatite; bacterial glycolytic enzymes
Marketed Cavity Protection Toothpaste	Marketed Cavity Protection Toothpaste	Procter and Gamble	marketed	Fluoride-based remineralizing agent	Tooth enamel hydroxyapatite; oral bacterial metabolism

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bisphosphonate class)

· 2 drugs in this class
Amgen · 2 drugs in this class
National Taiwan University Hospital · 2 drugs in this class
Sanofi · 2 drugs in this class
Ludwig-Maximilians - University of Munich · 2 drugs in this class
Chinese University of Hong Kong · 1 drug in this class
Chinese Society of Lung Cancer · 1 drug in this class
Aarhus University Hospital · 1 drug in this class
Eisai Inc. · 1 drug in this class
Daiichi Sankyo Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). risedronate combine — Competitive Intelligence Brief. https://druglandscape.com/ci/risedronate-combine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing